Patent ID: 9642830
Date: 2017-05-09
CPC Classifications: A61K,A61P,C12Q,G01N

Claim:
1. A method of treating a hepatitis B viral (HBV) infection in a subject, the method comprising administering a pharmaceutically effective amount of a STING agonist to the subject, wherein the STING agonist comprises at least one selected from the group consisting of 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), methoxyvone, 6,4′-dimethoxyflavone, 4′-methoxyflavone, 3′,6′-dihydroxyflavone, 7,2′-dihydroxyflavone, daidzein, formononetin, retusin 7-methyl ether, and any combinations thereof.